The US Food and Drug Administration has made a "green list" import alert to stop unapproved and unauthorised glucagon-like peptide 1 (GLP-1) drug ingredients from entering the US.
Due to shortages of the FDA-approved GLP-1 drugs that are used to treat type 2 diabetes and weight management, some patients consumed drug variants.
Read Article
#GLP-1
#EmergingDrugTrends